Table 1 Patient characteristics.

From: Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

Patient

Age (years)

Gender

Smoking

Histology

EGFR mutation at initial diagnosis

Line of treatment

KU-01

65

Female

Never

adeno

E746-A750 del

3rd

KU-02

71

Male

Never

adeno

E746-A750 del

6th

KU-03

71

Female

Never

adeno

L858R

6th

KU-04

68

Female

Never

adeno

L858R

4th

KU-05

75

Female

Never

adeno

L858R

3rd

KU-06

78

Male

Former

adeno

L858R

4th

KU-07

81

Female

Never

adeno

E746-A750 del

3rd

KU-08

58

Female

Former

adeno

E746-A750 del

4th

KU-09

89

Female

Never

adeno

L858R

4th

  1. EGFR, epidermal growth factor receptor.